ETOP/EORTC trial to evaluate denosumab for treating patients with advanced non-small cell lung cancer | EORTC | Health , Preventive health | Scoop.it
From www.eortc.org - February 5, 2015 12:12 PM

The ETOP 5-12/EORTC 08111 – SPLENDOUR (Survival imProvement in Lung cancEr iNduced by DenOsUmab therapy) trial will evaluate the addition of denosumab to standard first-line anticancer treatment in advanced NSCLC. It is thought that denosumab, by binding to the receptor activator of the nuclear factor-KappaB ligand, a protein that triggers bone removal, might help control skeletal related events and would eventually improve survival in NSCLC patients. This drug is already approved for postmenopausal women with osteoporosis, prevention of bone complications in patients with bone metastases from solid tumors, and treatment of patients with giant cell tumor of the bone.


Via Krishan Maggon